ANGIOMAX
Total Payments
$32,350
Transactions
7
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $32,350 | 7 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $32,350 | 7 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ENDOvascular Interventions with AngioMAX The ENDOMAX Trial | The Medicines Company | $17,350 | 0 |
| Carotid with Bivalirudin Angioplasty COBRA study | The Medicines Company | $15,000 | 0 |
Top Doctors Receiving Payments for ANGIOMAX
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Newport, RI | $32,350 | 7 |
Ad
Manufacturing Companies
- The Medicines Company $32,350
Product Information
- Type Drug
- Total Payments $32,350
- Total Doctors 0
- Transactions 7
About ANGIOMAX
ANGIOMAX is a drug associated with $32,350 in payments to 0 healthcare providers, recorded across 7 transactions in the CMS Open Payments database. The primary manufacturer is The Medicines Company.
Payment data is available from 2017 to 2017. In 2017, $32,350 was paid across 7 transactions to 0 doctors.
The most common payment nature for ANGIOMAX is "Unspecified" ($32,350, 100.0% of total).
ANGIOMAX is associated with 2 research studies, including "ENDOvascular Interventions with AngioMAX The ENDOMAX Trial" ($17,350).